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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
β-galactosidase from Kluyveromyces lactis in Colief® and a reduction of 
gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Cross Vetpharm Group UK Ltd, submitted for authorisation of a health claim 
pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, 
the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to β-galactosidase from Kluyveromyces lactis in Colief® and a 
reduction of gastrointestinal discomfort. The Panel considers that the food is sufficiently characterised in relation 
to the claimed effect. A reduction of gastrointestinal discomfort is a beneficial physiological effect for infants and 
young children. The applicant provided two human intervention studies for the substantiation of the health claim. 
No conclusions could be drawn from one of the two studies for the scientific substantiation of the claim, as the 
information provided in the publication and that supplied later by the applicant was inadequate to allow a 
scientific evaluation. The second study with methodological limitations showed an effect of the food on crying 
time in infants fed exclusively with milk. This study also provided some evidence for the proposed mechanism by 
which β-galactosidase could exert the claimed effect. In weighing the evidence, the Panel took into account that 
one study with methodological limitations showed an effect of β-galactosidase from Kluyveromyces lactis in 
Colief
®
 on infant crying time, that no other human studies in which these results have been replicated were 
provided, and that there was some evidence for a mechanism by which the food could exert the claimed effect. 
The Panel concludes that the evidence provided is insufficient to establish a cause and effect relationship 
between the consumption of β-galactosidase from Kluyveromyces lactis in Colief® and a reduction of 
gastrointestinal discomfort. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following an application from Cross Vetpharm Group UK Ltd, submitted for authorisation of a health 
claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the 
United Kingdom, the European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to β-galactosidase from Kluyveromyces lactis in Colief® and a reduction of gastrointestinal 
discomfort. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The food that is the subject of the health claim is ‘Colief®/lactase enzyme produced by controlled 
fermentation of Kluyveromyces lactis’. Ingested lactose is hydrolysed by lactase, an enzyme of the 
microvillus membrane of the enterocytes, into its components, glucose and galactose. The exogenous 
enzymes which are used to hydrolyse lactose are microbial β-galactosidases. The β-galactosidase 
which is the subject of the health claim is derived from the yeast Kluyveromyces lactis. The Panel 
considers that the food, β-galactosidase from Kluyveromyces lactis in Colief®, which is the subject of 
the health claim, is sufficiently characterised in relation to the claimed effect. 
The claimed effect proposed by the applicant is ‘reduces the lactose load of the infant’s feed and 
improves the consequences of lactose maldigestion in colicky infants unable to effectively digest all 
the lactose in their feed’. The target population proposed by the applicant is ‘infants prior to weaning, 
aged up to 4–5 months with signs of colic, i.e. excessive crying and associated features of lactose 
overload’. Upon a request for clarification, the applicant indicated that ‘reduction of gastrointestinal 
discomfort’ was the claimed effect and that infant crying time was the outcome measure. The Panel 
considers that a reduction of gastrointestinal discomfort is a beneficial physiological effect for infants 
and young children. 
The applicant provided two human intervention studies for the substantiation of the health claim. 
In a randomised, double-blind, cross-over study, 14 infants were fed, for one week, formula to which 
β-galactosidase from Kluyveromyces lactis or placebo was added, with a two-day wash-out period in 
between. Infants were included in the study if they exhibited ‘full force’ crying for three or more 
hours a day for three or more days a week. Crying time was assessed using parents’ diaries. Upon 
repeated requests from EFSA for more details on the statistical analysis, the applicant indicated that it 
was not possible to retrieve any statistical analysis plan or full study report 18 years after publication 
of the study. The Panel notes that the information provided in the publication and that supplied by the 
applicant in reply to requests for additional information was inadequate to allow a scientific 
evaluation. The Panel considers that no conclusions can be drawn from this study for the scientific 
substantiation of the claim. 
Another randomised, double-blind, cross-over study included 53 infants. The two cross-over periods 
lasted for 10 days each with a 5-day wash-out period in between. In order to be eligible for the study, 
infants had to exhibit for at least 14 days ‘full force’ crying for more than three hours per day for 
three days or more per week, together with spasm, lower limb flexure and diarrhoea. Formula-fed 
infants were given formula to which β-galactosidase preparation was added. For breast-fed infants, 
mothers expressed the fore-milk into a teaspoon to which β-galactosidase preparation was added. 
During the control period a placebo was used. 
Outcome measures were crying time and breath hydrogen concentration. Responders were defined 
a priori as those achieving a reduction of at least 45 % in both crying time and breath hydrogen 
concentrations. 
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The outcome variables were analysed only in the population of completers (n = 46 for crying time; 
n = 34 for breath hydrogen concentrations) and for the per-protocol (PP) population of compliers 
(n = 32 for crying time; n = 25 for breath hydrogen concentrations) but not in the intention-to-treat 
population (i.e. all the infants randomised for the study). The Panel notes that only 47 % of the infants 
randomised completed the study as planned (PP population), and that the PP analysis is at risk of 
selection bias. 
The responder analysis was restricted to a subset of 34 infants for whom data on both crying time and 
breath hydrogen concentrations were available. Of these, nine infants (26 %) were classified as 
responders following consumption of β-galactosidase, while no infant fulfilled the responder criteria 
when consuming placebo. The difference in the numbers of responders to β-galactosidase and to 
placebo, respectively, was statistically significant (p = 0.002). The applicant also provided 
information on responders considering only crying time for the completers’ population (n = 46) and 
the PP population (n = 32). In the completers’ population, 16 infants were classified as responders 
following consumption of β-galactosidase, while three infants qualified as responders when 
consuming placebo. In the PP population, 15 infants were classified as responders following 
consumption of β-galactosidase, while two infants qualified as responders when consuming placebo. 
Statistical analyses were also performed for absolute differences in crying time following 
consumption of β-galactosidase and placebo. In the population of completers (n = 46), there were no 
statistically significant differences in crying time between β-galactosidase and placebo. In the PP 
population (n = 32), crying time was significantly lower during the consumption of β-galactosidase 
(median: 520 minutes) than for placebo (median: 872.5 minutes; p = 0.0052). 
The areas under the curve for breath hydrogen concentrations were significantly lower during 
consumption of β-galactosidase than for placebo in both the completers’ population (6.0 ppm vs. 
11.5 ppm; p < 0.0001) and the PP population (6.0 ppm vs. 9.5 ppm; p < 0.0052). 
The Panel considers that this study with methodological limitations (no intention-to-treat analysis, 
PP analysis at risk of bias) shows an effect of β-galactosidase from Kluyveromyces lactis in Colief® 
on crying time in infants fed exclusively with milk. The Panel considers that this study also provides 
some evidence for the proposed mechanism by which β-galactosidase could exert the claimed effect. 
In weighing the evidence, the Panel took into account that one study with methodological limitations 
showed an effect of β-galactosidase from Kluyveromyces lactis in Colief® on infant crying time, that 
no other human studies in which these results have been replicated were provided, and that there is 
some evidence for a mechanism by which the food could exert the claimed effect. 
The Panel concludes that the evidence provided is insufficient to establish a cause and effect 
relationship between the consumption of β-galactosidase from Kluyveromyces lactis in Colief® and a 
reduction of gastrointestinal discomfort. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 10/06/2014. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 On 11/07/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 06/08/2014, EFSA received the applicant’s reply. 
 The scientific evaluation procedure started on 11/08/2014. 
 On 19/09/2014, the NDA Panel agreed on a list of questions for the applicant to provide 
additional information to accompany the application and the scientific evaluation was 
suspended on 23/09/2014, in compliance with Article 16(1) of Regulation (EC) No 
1924/2006. 
 On 20/11/2014, EFSA received the applicant’s reply and the scientific evaluation was 
restarted, in compliance with Article 16(1) of Regulation (EC) No 1924/2006. 
 On 22/01/2015, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application and the 
scientific evaluation was suspended on 28/01/2015, in compliance with Article 16(1) of 
Regulation (EC) No 1924/2006. 
 On 13/03/2015, EFSA received the applicant’s reply and the scientific evaluation was 
restarted, in compliance with Article 16(1) of Regulation (EC) No 1924/2006. 
 During its meeting on 30/06/2015, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to β-galactosidase 
from Kluyveromyces lactis in Colief
®
 and a reduction of gastrointestinal discomfort. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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opinion on the scientific substantiation of a health claim related to: β-galactosidase from 
Kluyveromyces lactis in Colief
®
 and a reduction of gastrointestinal discomfort. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of β-galactosidase from Kluyveromyces lactis in Colief®, a positive assessment of its safety 
or a decision on whether β-galactosidase from Kluyveromyces lactis in Colief® is, or is not, classified 
as a foodstuff. It should be noted that such an assessment is not foreseen in the framework of 
Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address 
Cross Vetpharm Group UK, Ltd, Bryn Cefni Industrial Park, Llangefni, Anglesey LL77 7XA, Wales, 
United Kingdom. 
Food/constituent as stated by the applicant 
According to the applicant, the food which is the subject of the claim is ‘Colief®/lactase enzyme 
produced by controlled fermentation of Kluyveromyces lactis’. 
Health relationship as claimed by the applicant 
According to the applicant, the health relationship relates to ‘the alleviation of the clinical features of 
secondary lactose maldigestion due to lactose overload [in infants]. Lactase enzyme added to the milk 
feed prior to ingestion, catalyses hydrolysis of the disaccharide lactose into molar equivalents of the 
monosaccharides glucose and galactose which the infant can absorb. This reduces the amount of 
lactose entering the colon and undergoing microbial fermentation, which lessens the adverse effects in 
susceptible infants. […] The outcome measures used to assess the claimed effect in infants are 
measurement of breath hydrogen (objective measure) and infant crying time (quasi-objective 
measure). […] The rationale for using crying time as a marker is that excessive crying time is a 
diagnostic feature of infantile colic, of which lactose overload is one possible cause.’ 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: ‘Colief®/lactase enzyme 
reduces the lactose load of the infant’s feed and improves the consequences of lactose maldigestion in 
colicky infants unable to effectively digest all the lactose in their feed.’ 
Specific conditions of use as proposed by the applicant 
According to the applicant, ‘for milk for imminent use the quantity required is four drops of the 
lactase enzyme added to each feed (expressed breast milk, reconstituted formula or ready-to-use 
formula). The drops are added 30 minutes before the commencement of feeding. For feeds prepared at 
least four hours in advance of feeding, two drops are used. It is estimated that this dosing regimen 
converts at least 60 % of the available lactose per feed to molar equivalents of glucose and galactose. 
For breast feeding, four drops are added to a few tablespoons of expressed breast milk and given to 
the infant by sterilised spoon, following which breastfeeding is initiated as normal.’ The applicant 
specified that the target population for the claim is ‘infants prior to weaning, aged up to 4–5 months 
with signs of colic, i.e. excessive crying and associated features of lactose overload (spasm, lower 
limb flexure and diarrhoea)’. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is ‘Colief®/lactase enzyme produced by controlled 
fermentation of Kluyveromyces lactis’. 
Ingested lactose is hydrolysed by lactase, an enzyme of the microvillus membrane of the enterocytes, 
into its components, glucose and galactose. The exogenous enzymes which are used to hydrolyse 
lactose are microbial β-galactosidases mainly derived from Kluyveromyces lactis, Kluyveromyces 
fragilis and Aspergillus oryzae (EFSA NDA Panel, 2010). 
β-galactosidase from Kluyveromyces lactis and reduction of gastrointestinal discomfort 
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The β-galactosidase which is the subject of the health claim is derived from the yeast Kluyveromyces 
lactis. 
According to the applicant, the β-galactosidase which is produced by Kluyveromyces lactis is stable 
and active over a pH range of 6–8. 
Information pertaining to the stability of the commercial product containing β-galactosidase from 
Kluyveromyces lactis produced by the applicant was provided. The lactase enzyme activity in the 
commercial product is 4 500 Food Chemical Codex Neutral Lactase Units (FCC NLU) per gram. It is 
supplied in liquid form. 
The Panel notes that β-galactosidase from Kluyveromyces lactis is a well-characterised enzyme and 
that its activity can be measured in foods by established methods. 
The Panel considers that the food, β-galactosidase from Kluyveromyces lactis in Colief®, which is the 
subject of the health claim, is sufficiently characterised in relation to the claimed effect. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is ‘reduces the lactose load of the infant’s feed and 
improves the consequences of lactose maldigestion in colicky infants unable to effectively digest all 
the lactose in their feed’. The target population proposed by the applicant is ‘infants prior to weaning, 
aged up to 4–5 months with signs of colic, i.e. excessive crying and associated features of lactose 
overload (spasm, lower limb flexure and diarrhoea)’. 
Upon a request for clarification, the applicant indicated that ‘reduction of gastrointestinal discomfort’ 
was the claimed effect and that infant crying time was the outcome measure. 
Unexplained bouts of crying in young infants have been traditionally attributed to gastrointestinal 
disturbances and pain (Shamir et al., 2013). The term infant colic is commonly used to reflect this 
situation in young infants. Infant colic has been included in the list of childhood functional 
gastrointestinal disorders of the Rome III Coordinating Committee, with diagnostic criteria based on 
infant crying time and frequency (Hyman et al., 2006). The Panel considers that crying time can be 
used to assess gastrointestinal discomfort in infants diagnosed with infant colic. 
The Panel considers that a reduction of gastrointestinal discomfort is a beneficial physiological effect 
for infants and young children. 
3. Scientific substantiation of the claimed effect 
The applicant indicated that the lactase enzyme added to the milk feed prior to ingestion catalyses the 
hydrolysis of the disaccharide lactose into molar equivalents of the monosaccharides glucose and 
galactose, which infants can absorb, and that this would reduce the amount of lactose entering the 
colon and undergoing microbial fermentation, and thus gastrointestinal discomfort in susceptible 
infants. The applicant claims that breath hydrogen concentrations are an indirect measure of 
undigested carbohydrates, including lactose, in the gastrointestinal tract. 
The applicant performed a literature search in Medline, Embase, Embase Alert and the Cochrane 
Library for publications in English using the following key words: ‘lactase’ AND ‘infant colic’ OR 
‘cry$3’ OR ‘breath hydrogen’ AND ‘infant$1’. Additional searching was also done by hand. Studies 
were included if they were of a ‘sound design’ with a suitable control/treatment period and washout 
period, if they investigated the effect of lactase enzyme on indicators of ‘lactose overload’ in infants 
aged up to six months and prior to commencement of weaning, and if they included lactase enzyme 
added to milk (i.e. studies were excluded in cases in which lactase enzyme was given directly to 
infants before or following a milk feed). 
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The applicant provided two human intervention studies (Kearney et al., 1998; Kanabar et al., 2001) 
which assessed the effect of the food (i.e. β-galactosidase from Kluyveromyces lactis in Colief®) on 
infant crying time. One of the studies (Kanabar et al., 2001) also assessed the effect of Colief
®
 on 
breath hydrogen concentrations, an indirect indicator of fermentation of undigested carbohydrates (i.e. 
mainly lactose in infants fed exclusively milk). 
In a randomised, double-blind, cross-over study by Kearney et al. (1998), 14 infants (of whom 
13 completed; completers’ age and birth weight: 23–112 days, 2.9–4.7 kg) were fed parent-selected 
formula to which β-galactosidase from Kluyveromyces lactis or placebo (unspecified) was added 
24 hours before feeding for one week, with a two-day wash-out period in between. Infants were 
included in the study if they exhibited ‘full force’ crying for three or more hours a day for three or 
more days a week. 
In the original publication, the study was reported to have been carried out with ‘Lactaid®’ rather than 
with ‘Colief®’. Upon request for clarification and specification of the β-galactosidase used in the 
study, the applicant provided a signed statement which indicated that subsequent to publication of the 
study the commercial name of the product was changed from Lactaid
®
 to Colief
®
 and that the two 
products are identical. The applicant also stated that the enzymatic activity of the lactase enzyme at 
the time of the study was the same as the enzymatic activity in the current product (i.e. Colief
®
) for 
which the health claim is made. 
Following a request for clarification, the applicant indicated that the intended randomisation 
procedure (i.e. 6 blocks of 4 with 24 subjects in total) described in the publication could not be 
followed because of difficulties with recruitment. The applicant also stated that only 14 infants were 
randomised, that of these one infant was excluded from the analysis because ‘his/her age was outside 
the range specified in the inclusion criteria’ and that it has not been possible to retrieve any data for 
this excluded infant. The Panel notes that age was not indicated as an inclusion criterion in the 
publication and that no power calculations were provided. 
Crying time was assessed using parents’ diaries. In the publication it was reported that the analysis of 
crying time was based on a ‘model for a two-period crossover trial with a covariate’ (Jones and 
Kenward, 1989). Upon repeated requests from EFSA for more details on the statistical analysis, the 
applicant indicated that it was not possible to retrieve any statistical analysis plan or full study report 
18 years after publication of the study. 
The Panel notes that the information provided in the publication and that supplied by the applicant in 
reply to requests for additional information was inadequate to allow a scientific evaluation. 
The Panel considers that no conclusions can be drawn from this study for the scientific substantiation 
of the claim. 
The randomised, double-blind, cross-over study by Kanabar et al. (2001) included 53 infants aged 
between 3 and 13 weeks. The two cross-over periods lasted for 10 days each with a five-day washout 
period in between. In order to be eligible for the study, infants had to exhibit for at least 14 days ‘full 
force’ crying for more than three hours per day for three days or more per week, together with spasm, 
lower limb flexure and diarrhoea. 
Formula-fed infants were given formula to which two drops of β-galactosidase preparation was added 
four hours before feeding. For breast-fed infants, mothers expressed the fore-milk into a teaspoon to 
which four drops of β-galactosidase were added. Mothers then breast-fed as usual, and gave the 
treated fore-milk to the infant at the end of the feed. During the control period, a placebo (heat-
inactivated lactase) was used. 
In the publication it was reported that the β-galactosidase used in the trial was derived from 
Aspergillus. Upon request for clarification on the food used in the study, the applicant provided 
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signed statements indicating that the applicant was the sponsor of the study and that the applicant’s 
β-galactosidase product used in the study was sourced from Kluyveromyces lactis and not from 
Aspergillus. The Panel notes that an erratum which confirmed such information was published in 
2007. 
Compliance with the study protocol was assessed using returned bottles in which the study products 
had been distributed in a volume of 7 ml. Infants were considered to be non-compliant when the 
contents in the returned bottles exceeded 3.5 ml. 
The Panel notes the poor reporting of the published study (Kanabar et al., 2001), which was 
communicated to the applicant in several requests for additional information. The description of the 
study methods and results which is given below summarises the information provided by the applicant 
in reply to EFSA’s requests. 
Outcome measures of the study were crying time and breath hydrogen concentration. Crying time was 
assessed using daily records filled in by the parents. Breath hydrogen was measured (using a portable 
hydrogen monitor) during the last two days at the end of each period. Measurements were performed 
before feeding, and at 10-minute intervals thereafter up to a maximum of 120 minutes or until breath 
hydrogen returned to the pre-feed baseline values. All readings over the pre-prandial baseline were 
summed to give an approximate area under the curve (AUC) value. Responders were defined a priori 
as those achieving a reduction of at least 45 % in both crying time and breath hydrogen 
concentrations. According to the applicant, the responder analysis was the pre-specified primary 
endpoint of the study. No reasons were provided for choosing a cut-off of 45 % reduction in both 
outcome variables. 
The outcome variables were analysed only in the population of completers (n = 46 for crying time; 
n = 34 for breath hydrogen concentrations) and for the per-protocol (PP) population of compliers 
(n = 32 for crying time; n = 25 for breath hydrogen concentrations). The applicant claimed that no 
analyses could be conducted in the intention-to-treat (ITT) study population (all subjects randomised, 
n = 53). The Panel notes that only 47 % of the infants randomised completed the study as planned 
(PP population), and that the PP analysis is at risk of selection bias. 
The responder analysis was restricted to a subset of 34 infants for whom data on both crying time and 
breath hydrogen concentrations were available. Of these, nine infants (26 %, 95 % binomial 
confidence interval: 12.9–44.4 %) were classified as responders following consumption of 
β-galactosidase, while no infant fulfilled the responder criteria when consuming placebo. The 
difference in the numbers of responders to β-galactosidase and to placebo, respectively, was 
statistically significant (p = 0.002, Fisher’s exact test). In the PP population (n = 24), nine infants 
(38 %; 95 % binomial confidence interval: 18.8–59.4 %) were classified as responders. The applicant 
also provided information on responders considering only crying time for both the completers’ 
population and the PP population. In the completers’ population (n = 46), 16 infants were classified as 
responders following consumption of β-galactosidase, while 3 infants qualified as responders when 
consuming placebo. The difference in the numbers of responders (considering crying time only) to 
β-galactosidase and to placebo, respectively, was statistically significant (p = 0.0015, Fisher’s exact 
test). In the PP population (n = 32), 15 infants were classified as responders following consumption of 
β-galactosidase, while 2 infants qualified as responders when consuming placebo. 
Statistical analyses were also performed for absolute differences in crying time following 
consumption of β-galactosidase and placebo, respectively. As the data had a non-normal distribution, 
the non-parametric method proposed by Koch (1972) was applied, in order to examine the effects of 
treatment, period and order of the treatments. Results are given as medians and interquartile ranges 
(IQRs). In the population of completers (n = 46), there were no statistically significant differences in 
crying time between β-galactosidase (median, IQR: 657.5 minutes, 320–1 200 minutes) and placebo 
(median, IQR: 847.5 minutes, 515–1 515 minutes; p = 0.09). Results of the effect of period and 
β-galactosidase from Kluyveromyces lactis and reduction of gastrointestinal discomfort 
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treatment order were not reported. In the PP population (n = 32), crying time was significantly lower 
during the consumption of β-galactosidase (median, IQR: 520 minutes, 305–1 192.5 minutes) than for 
placebo (median, IQR: 872.5 minutes, 595–1 585 minutes; p = 0.0052). The effects of period and 
treatment order were not statistically significant. 
The AUC for breath hydrogen concentrations were significantly lower during consumption of 
β-galactosidase than for placebo in both the completers’ population (median, IQR: 6.0 ppm  
(3.0–7.0 ppm) vs. 11.5 ppm (6.0–22.0 ppm); p < 0.0001) and the PP population (median, IQR: 
6.0 ppm (4.0–7.0 ppm) vs. 9.5 ppm (5.5–23.0 ppm); p < 0.0052). 
The Panel considers that this study with methodological limitations (no ITT analysis, PP analysis at 
risk of bias) shows an effect of β-galactosidase from Kluyveromyces lactis in Colief® on crying time 
in infants fed exclusively with milk. The Panel considers that this study also provides some evidence 
for the proposed mechanism by which β-galactosidase could exert the claimed effect. 
In weighing the evidence, the Panel took into account that one study with methodological limitations 
showed an effect of β-galactosidase from Kluyveromyces lactis in Colief® on infant crying time, that 
no other human studies in which these results have been replicated were provided, and that there is 
some evidence for a mechanism by which the food could exert the claimed effect. 
The Panel concludes that the evidence provided is insufficient to establish a cause and effect 
relationship between the consumption of β-galactosidase from Kluyveromyces lactis in Colief® and a 
reduction of gastrointestinal discomfort. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, β-galactosidase from Kluyveromyces lactis in Colief®, is sufficiently characterised 
in relation to the claimed effect. 
 The claimed effect proposed by the applicant is ‘reduces the lactose load of the infant’s feed 
and improves the consequences of lactose maldigestion in colicky infants unable to 
effectively digest all the lactose in their feed’. The target population proposed by the 
applicant is ‘infants prior to weaning, aged up to 4–5 months with signs of colic, i.e. 
excessive crying and associated features of lactose overload (spasm, lower limb flexure and 
diarrhoea)’. Upon a request for clarification, the applicant indicated that ‘reduction of 
gastrointestinal discomfort’ was the claimed effect and that infant crying time was the 
outcome measure. A reduction of gastrointestinal discomfort is a beneficial physiological 
effect for infants and young children. 
 The evidence provided is insufficient to establish a cause and effect relationship between the 
consumption of β-galactosidase from Kluyveromyces lactis in Colief® and a reduction of 
gastrointestinal discomfort. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on β-galactosidase from Kluyveromyces lactis and a reduction of 
gastrointestinal discomfort pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 
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ABBREVIATIONS 
AUC  area under the curve 
IQR  interquartile range 
ITT  intention-to-treat 
PP  per-protocol 
ppm  part per million 
